UK competition authority escalates investigation of Oticon Medical sale
Neither Demant not Cochlear has wanted to comment on the UK competition authority, which is therefore bringing its merger inquiry into phase II.
by albert rønning-andersson, translated by daniel pedersen
The UK Competition and Markets Authority, CMA, expressed concerns earlier this month regarding Demant selling off its Oticon Medical division to Australian Cochlear. After both parties declined an invitation to comment, the inquiry is moving into phase II. Phase one started in back in October.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
